Crown Bioscience and The Jackson Laboratory (JAX) have formed an agreement to improve the development and accessibility of innovative research models and pre-clinical services to the global biomedical research community.

The agreement between Crown Bioscience, a global technology platform for oncology, and cardiovascular and metabolic disease, and JAX, a non-profit biomedical research institution and worldwide provider of high-quality research models and services, facilitates the shared objective of both organizations to accelerate and advance the rate of pre-clinical research and discovery.

As part of the agreement CrownBio will advance the use of JAX Mice in client research studies. CrownBio will increase the utilization and improve access of JAX research models, including humanized NSG and NSG-SGM3, thus advancing the research and translational efforts of organizations globally.

JAX research scientists will have select access to CrownBio’s pre-clinical contract laboratory services, providing JAX scientists with additional resources and facilities in which to continue the search for cures for cancer and other diseases.

“The agreement with JAX heralds a significant step forward for Oncology and Immuno-Oncology pre-clinical research,” said Jean-Pierre Wery, chief executive officer, Crown Bioscience. “The utilization of JAX’s scientific-leading humanized and translational models in combination with our PDX technology platforms will ensure the greatest potential for translatable drug development.”

Research teams at JAX, focused on understanding the genetic and biochemical signatures that can be targeted by next-generation precision medicines, will begin leveraging CrownBio’s research services in oncology and CVMD to generate new insights into therapeutic approaches to target disease.

“The Jackson Laboratory’s mission is to empower the global biomedical community in our shared quest to improve human health. By harnessing our complementary strengths, this agreement allows us to propel scientific research and drug discovery globally by improving accessibility to the most advanced and highest quality pre-clinical research models and services,” said Auro Nair, president, JAX mice, clinical and research services. “Additionally, JAX research teams will be able to advance basic biological discoveries to therapies much more rapidly by utilizing the world’s largest collection of PDX and cell-line models and services from CrownBio.”